Clincosm LogoSign in Get a demo

A Phase I/II Study to Assess the Safety and Efficacy of TKI258 for the Treatment of Refractory Advanced/Metastatic Renal Cell Cancer

Sponsor
Novartis Pharmaceuticals (Industry)
Overall Status
Completed
CT.gov ID
NCT00715182
Collaborator
(none)
87
Enrollment
12
Locations
1
Arm
48
Duration (Months)
7.3
Patients Per Site
0.2
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This is a phase I/II open-label study to delineate the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of TKI258. The eligible subject population consists of subjects who have been diagnosed with advanced or metastatic renal cell cancer that is refractory to standard therapy or for which no curative standard therapy exists.

Condition or Disease Intervention/Treatment Phase
Phase 1

Study Design

Study Type:
Interventional
Actual Enrollment :
87 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
A Phase I/II Multi-center, Open Label Study of TKI258 Administered Orally on an Intermittent Schedule in Adult Patients With Advanced or Metastatic Renal Cell Cancer (RCC)
Study Start Date :
Jul 1, 2008
Actual Primary Completion Date :
Jul 1, 2012
Actual Study Completion Date :
Jul 1, 2012

Arms and Interventions

Arm Intervention/Treatment
Experimental: TKI258

Drug: TKI258

Outcome Measures

Primary Outcome Measures

  1. Phase I: To determine the MTD of TKI258, administered orally on a 5 days on/2 days off schedule to adult patients with advanced or metastatic RCC whose diseases have progressed despite standard therapy or for whom no standard anticancer therapy exists. [at end of phase I]

  2. Phase II: To determine anti-tumor activity of TKI258 in advanced or metastatic RCC patients with predominant clear cell histology that have been previously treated with VEGF receptor tyrosine kinase inhibitor (sunitinib and/or sorafenib). [at end of phase II]

Secondary Outcome Measures

  1. To assess the safety profile of TKI258 [cycle 1: day 1,8,15,26; cycle 2: day 15, 28; cycle 3+: day 28 & at end of study]

  2. To assess the effect of TKI258 on plasma biomarkers, pre- and post-treatment [cycle 1: day 1,15,26; cycle 2: 15 & 28; every other cycles: day 28 & at end of study]

  3. To explore the pharmacokinetic and pharmacodynamic relationship [end of study]

  4. To characterize the single and multiple-dose PK profiles of oral TKI258 [cycle 1: day 1, 8, 15 &26; cycle 2 & 3: day 15 & 28]

  5. Progression free survival and over all survival [end of study]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:

  • For phase I, confirmed advanced/ metastatic renal cell carcinoma for which no other therapeutic options exist.

  • For phase II, must have been previously treated with VEGF receptor tyrosine kinase inhibitor (sunitinib and/or sorafenib).

  • For phase II, must have at least one measurable lesion at baseline.

  • For both phase I & II, measurable histologically or cytology confirmed progressive metastatic renal cell carcinoma with predominant clear cell histology (>50%).

  • At least 4 weeks must have elapsed since any prior anti-cancer therapy (6 weeks for nitrosoureas or mitomycin C).

  • Must have recovered from adverse events (to grade 1 or less toxicity according to CTCAE 3.0) due to agents administered more than 28 days earlier.

  • Must be eighteen years of age or older

  • ECOG performance status 0 or 1.

  • Must meet baseline laboratory requirement

  • Life expectancy greater than or equal to 12 weeks.

  • Signed and witnessed informed consent prior to any screening procedures.

Exclusion Criteria:

  • Concurrent therapy with any other investigational agent within 28 days prior to baseline.

  • Pregnant or breast feeding women.

  • Clinically significant cardiac disease (New York Heart Association, Class III or IV) or impaired cardiac function or clinically significant cardiac diseases.

  • Uncontrolled infection.

  • Diabetes mellitus with signs of clinically significant peripheral vascular disease.

  • Previous pericarditis; clinically significant pleural effusion in the previous 12 months or current ascites requiring two or more interventions/month.

  • Known pre-existing clinically significant disorder of the hypothalamic-pituitary axis, adrenal or thyroid glands.

  • Prior acute or chronic pancreatitis of any etiology.

  • Acute and chronic liver disease and all chronic liver impairment.

  • Malabsorption syndrome or uncontrolled gastrointestinal symptoms (such as nausea, diarrhea and vomiting) with toxicity greater than NCI CTCAE grade 2.

  • Other severe, acutem or chronic medical or psychiatric condition or laboratory abnormality that may interfere with the interpretation of study results and, in the judgement of the investigator, would make the subject inappropriate for this study.

  • Treatment with any of the medications that have a potential risk of prolonging the QT interval or inducing Torsades de Points and the treatment cannot be discontinued or switched to a different medication prior to starting study drug.

  • Use of ketoconazole, erythromycin, carbamazapine, phenobarbital, rifampin, phenytoin and quinidine 2 weeks prior to baseline.

  • Major surgery within 28 days prior to starting study drug or who have not recovered from side effects of such therapy.

  • Known diagnosis of HIV infection (HIV testing is not mandatory).

  • History of another clinically significant primary malignancy that requires active intervention.

  • Patients with brain metastases as assessed by radiologic imaging.

  • Alcohol or substance abuse disorder.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Novartis Investigative Site San Francisco California United States
2 Novartis Investigative Site Durham North Carolina United States 27710
3 Novartis Investigative Site Seattle Washington United States 98109-1023
4 Novartis Investigative Site Bordeaux Cedex France 33075
5 Novartis Investigative Site Villejuif Cedex France 94805
6 Novartis Investigative Site Hannover Germany 30625
7 Novartis Investigative Site München Germany 81675
8 Novartis Investigative Site Rotterdam Netherlands 3075 EA
9 Novartis Investigative Site Madrid Spain 28041
10 Novartis Investigative Site Taipei Taiwan, ROC Taiwan 112
11 Novartis Investigative Site Taichung Taiwan 40705
12 Novartis Investigative Site Taipei Taiwan 10002

Sponsors and Collaborators

  • Novartis Pharmaceuticals

Investigators

  • Study Director: Novartis Pharmaceuticals, Novartis Pharmaceuticals

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

None provided.
Responsible Party:
Novartis Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT00715182
Other Study ID Numbers:
  • CTKI258A2107
  • 2007-004391-39
First Posted:
Jul 15, 2008
Last Update Posted:
Dec 21, 2020
Last Verified:
Jan 1, 2013
Keywords provided by Novartis Pharmaceuticals
Renal Cell Cancer
Additional relevant MeSH terms:
Carcinoma, Renal Cell

Study Results

No Results Posted as of Dec 21, 2020